Remicade Gets Priority Review For Children…

Remicade has now received priority review by the FDA for treatment of children.

More information, Click here…

As TheStreet.com reported:

“In the clinical trial, after 10 weeks of treatment, 88.4% of children with moderately to severely active Crohn’s disease who didn’t adequately respond to conventional treatment responded to Remicade. After one year, 63.5% of patients who took Remicade every eight weeks showed a response to the drug. The disease was in remission in more than half of the patients on the drug after one year.”

4 April 2006 | Crohn's Disease, Crohn's Treatments, Crohn's Research | Comments